Why Trevi Therapeutics, Inc.’s (TRVI) Stock Is Down 6.26%
As of Tuesday, September 15, Trevi Therapeutics, Inc.’s TRVI share price has dipped by 6.26%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Commentary & Analysis
Why Trevi Therapeutics, Inc.’s (TRVI) Stock Is Down 6.01%
As of Friday, August 28, Trevi Therapeutics, Inc.’s TRVI share price has dipped by 6.01%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Trevi Therapeutics, Inc.’s (TRVI) Stock Is Up 6.56%
As of Tuesday, July 21, Trevi Therapeutics, Inc.’s TRVI share price has surged by 6.56%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Trevi Therapeutics, Inc.’s (TRVI) Stock Is Down 5.35%
As of Monday, July 20, Trevi Therapeutics, Inc.’s TRVI share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Trevi Therapeutics, Inc.’s (TRVI) Stock Is Up 7.06%
As of Friday, July 17, Trevi Therapeutics, Inc.’s TRVI share price has surged by 7.06%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | TRVI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,263.9 | $608.6 | 56% |
|
| Shares Out (Mil) | 161.8 | 43.1 | 72% |
|
| Institutional Ownership | 99.2% | 83.7% | 86% |
|
| Float (Mil) | 118.3 | 45.1 | 64% |
|
| Beta | 1.07 | 0.73 | 64% |
|
| Avg Daily Volume (000s) | 1,323 | 309 | 76% |
|
| Price Change (52-week) |
63.0% | 65.2% | 87% |
|
| Growth | TRVI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (5.5%) | (1.5%) | 33% |
|
| EPS (5yr) | 29.5% | 15.1% | 81 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 30.5% | (15.0%) | 86% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($0.133) | ($0.479) | ($0.577) | |
| Month Ago EPS | ($0.133) | ($0.479) | ($0.577) | |
| # Rev Up | 1 | 2 | 2 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.129) | ($0.469) | ($0.558) | |
| Year/Year Chg | 20.9% | 51.1% | 114.5% | |
| Financials | TRVI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($51) | ($11) | 16% |
|
| EPS (TTM) | ($0.351) | ($0.700) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($53) | ($6) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($63) | $5 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 13% |
|
| Enterprise Value (Q1) (Mil) | $2,319 | $524 | 51% |
|
| Valuation | TRVI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.03 | 2.60 | 86% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TRVI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | 0.8% | na |
|
| ROA | (19.0%) | (22.5%) | 21% |
|
| ROE | (19.7%) | (21.8%) | 23% |
|
| Liabilities to Assets | 2.7% | 32.8% | 1% |
|
| F-Score | 3 | 3 | 18% |
|
Trevi Therapeutics, Inc. did not pass any screens on 9/14/2026.
